Serina Therapeutics, Inc. (SER) income statement
SERNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$1.35−0.01 (-1.10%)
Close on Nov 18, 2026Market cap $34.29MP/E –Yield –
Serina Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- -18478.5%
- Net margin
- -16288.5%
- Return on equity, FY2025
- -6351.7%
Financial strength
- Current ratio
- 6.65
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 612.0%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?